in vitro News and Research

RSS

Advanced 3D/4D ultrasound to guide embryo transfer during IVF reduces risk of ectopic pregnancy

Using advanced 3D/4D ultrasound to guide embryo transfer during in vitro fertilization (IVF) significantly reduces a woman's risk of ectopic pregnancy and its associated complications, Robert Gergely, M.D., medical director, 3D Sonography Center of Beverly Hills, reported today.

30 Jun 2010

ESHRE's EIM: Europe leads in Assisted Reproduction Technology

Europe leads the world in Assisted Reproduction Technology (ART) with most cycles initiated in the region, the 26th Annual Meeting of the European Society of Human Reproduction and Embryology heard today (Wednesday 30 June).

30 Jun 2010

Molecular Biometrics' ViaMetrics-E procedure accurately predicts implantation rates in SET IVF cycles

Researchers from Molecular Biometrics, Inc. presented new data this week demonstrating that the company's ViaMetrics-E procedure more accurately predicts implantation rates in single embryo transfer (SET) cycles for patients undergoing infertility treatment. ViaMetrics-E is a rapid, non-invasive procedure used to enhance in vitro fertilization (IVF) outcomes by identifying viable embryos having the greatest reproductive potential.

30 Jun 2010

Genetic variation makes women sub-fertile, less likely to respond to ovarian stimulating hormones

Researchers have discovered that some women carry a genetic variation that makes them sub-fertile and less likely to respond to ovarian stimulating hormones during fertility treatment. The discovery opens the way to identifying these women and devising personalised fertility treatments that could bypass the problem caused by the genetic abnormality.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

Claros point-of-care system for PSA receives European CE Mark approval

Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced the CE Mark approval for its rapid quantitative point-of-care diagnostic platform, which can now be used for prostate specific antigen (PSA) testing throughout the European Union. The approved system consists of a small portable analyzer and credit card-sized disposable.

29 Jun 2010

Genetic variation can impact women's response to ovarian stimulating hormones

29 Jun 2010

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Affymetrix, Inc. and Signature Diagnostics AG today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix® microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.

29 Jun 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Female biology screens for the best sperm: Study

A new study has revealed that the female reproductive system is ‘choosy’ when it comes to inferior quality sperm and rejects the ‘advances’ of spermatozoa that are not good enough to create a pregnancy.

23 Jun 2010

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.

23 Jun 2010

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

Spanish scientists have proposed using human amniotic membrane as a new tool for repairing damaged human articular cartilage, which heals very poorly because of its low capacity for self-repair. Their research, published in the journal Cell and Tissue Banking, shows that the cellular density of the cartilage synthesised could be greater than that of the body's own natural cartilage.

23 Jun 2010

German IVF Register reports one-millionth treatment cycle in reproductive medicine

Dr. Klaus Buhler, President of the German IVF Register, has reported the one-millionth treatment cycle in reproductive medicine recorded by the IVF Register in Germany this year. Presently, ninety per cent of all centers for in-vitro fertilization (IVF) in Germany collect data from reproductive treatments using RecDate Advance by Merck Serono - a database system developed by the IT consulting firm CRITEX, and marketed under the name MedITEX IVF.

23 Jun 2010

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

Chocolate bar with resveratrol may help improve memory, learning skills

Wondering where you put the car keys? Can't remember what day of the week it is? Perhaps you need to eat a new kind of chocolate bar.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Discoveries in study and manipulation of human ES cells win first prize in research competition

World-recognized discoveries in the study and manipulation of human embryonic stem cells have won first prize in a prestigious applied research competition for a Hebrew University of Jerusalem researcher.

22 Jun 2010

Celator announces expansion of research agreement with Cephalon

Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

22 Jun 2010

in vitro News and Research

Advanced 3D/4D ultrasound to guide embryo transfer during IVF reduces risk of ectopic pregnancy

ESHRE's EIM: Europe leads in Assisted Reproduction Technology

Molecular Biometrics' ViaMetrics-E procedure accurately predicts implantation rates in SET IVF cycles

Genetic variation makes women sub-fertile, less likely to respond to ovarian stimulating hormones

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Claros point-of-care system for PSA receives European CE Mark approval

Genetic variation can impact women's response to ovarian stimulating hormones

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Female biology screens for the best sperm: Study

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

German IVF Register reports one-millionth treatment cycle in reproductive medicine

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Chocolate bar with resveratrol may help improve memory, learning skills

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Discoveries in study and manipulation of human ES cells win first prize in research competition

Celator announces expansion of research agreement with Cephalon

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News